. Erratum: Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed CellDeath Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol 2023 Mar 20:JCO2300439. doi: 10.1200/JCO.23.00439.
PMID: 36940394